Abstract
Objectives: Mice overexpressing SIRT6 live longer than wild-type mice while SIRT6 knockout mice exhibit similar degenerative phenotypes as individuals with Hutchinson-Gilford progeria syndrome (HGPS). Thus, we sought to test whether levels of SIRT6 are reduced in cells from individuals with HGPS and whether restored SIRT6 expression may impede premature aging phenotypes. Methods: Levels of endogenous SIRT6 and progerin in HGPS and normal fibroblasts were assessed by Western blotting and immunofluorescence. A tetracycline-inducible system was utilized to test whether progerin causes a rapid reduction in SIRT6 protein. SIRT6 was overexpressed in HGPS cells via lentiviral infection with biological endpoints including senescence-associated β-galactosidase (SA-β-gal) positivity, frequency of nuclear atypia, the number of 53BP1-positive DNA damage foci and growth rates. Results: Typical HGPS fibroblasts express lower levels of SIRT6 than fibroblasts from normal and atypical HGPS donors. Experimental induction of progerin did not cause a detectable reduction of SIRT6 protein. However, overexpression of SIRT6 in HGPS cells was associated with a reduced frequency of SA-β-gal positivity, fewer misshapen nuclei, fewer DNA damage foci, and increased growth rates. Conclusions: Typical HGPS fibroblasts exhibit reduced levels of SIRT6 protein via a mechanism that remains to be elucidated. Our findings suggest that restoring SIRT6 expression in HGPS cells may partially impede senescence and the formation of dysmorphic nuclei.
References
1.
Serio R: Unraveling the mysteries of aging through a Hutchinson-Gilford progeria syndrome model. Rejuvenation Res 2011;14:133-141.
2.
Eriksson M, Brown W, Gordon L, Glynn M, Singer J, Scott L, Erdos M, Robbins C, Moses T, Berglund P, et al: Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003;423:293-298.
3.
D'Apice R, Tenconi R, Mammi I, van den Ende J, Novelli G: Paternal origin of LMNA mutations in Hutchinson-Gilford progeria. Clin Genet 2004;65:52-54.
4.
Benson E, Lee S, Aaronson S: Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence. J Cell Sci 2010;123:2605-2612.
5.
Cao K, Blair C, Faddah D, Kieckhaefer J, Olive M, Erdos M, Nabel E, Collins F: Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J Clin Invest 2011;121:2833-2844.
6.
Scaffidi P, Gordon L, Misteli T: The cell nucleus and aging: tantalizing clues and hopeful promises. PLoS Biol 2005;3:e395.
7.
Berdasco M, Esteller M: Hot topics in epigenetic mechanisms of aging. Aging Cell 2012;11:181-186.
8.
Arancio W, Pizzolanti G, Genovese S, Pitrone M, Giordano C: Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review. Gerontology 2014;60:197-203.
9.
Bitterman K, Medvedik O, Sinclair D: Longevity regulation in Saccharomyces cerevisiae: linking metabolism, genome stability, and heterochromatin. Microbiol Mol Biol Rev 2003;67:376-399.
10.
Chen D, Guarente L: SIR2: a potential target for calorie restriction mimetics. Trends Mol Med 2007;13:64-71.
11.
Carafa V, Nebbioso A, Altucci L: Sirtuins and disease: the road ahead. Front Pharmaco 2012;3:4.
12.
Kugel S, Mostoslavsky R: Chromatin and beyond: the multitasking roles of SIRT6. Trends Biochem Sci 2014;29:72-81.
13.
Mostoslavsky R, Chua K, Lombard D, Pang W, Fischer M, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy M, et al: Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006;124:315-329.
14.
Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, Bar-Joseph Z, Cohen H: The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012;483:218-221.
15.
Jia G, Su L, Singhal S, Liu X: Emerging roles of SIRT6 on telomere maintenance, DNA repair, metabolism and mammalian aging. Mol Cell Biochem 2012;364:345-350.
16.
Tennen R, Chua K: Chromatin regulation and genome maintenance by mammalian SIRT6. Trends Biochem Sci 2011;36:39-46.
17.
Michishita E, McCord R, Berber E, Kioi M, Padilla-Nash H, Damian M, Cheung P, Kusumoto R, Karahara T, Barrett J, et al: SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 2008;52:492-496.
18.
Scaffidi P, Misteli T: Lamin A-dependent nuclear defects in human aging. Science 2006;312:1059-1063.
19.
Olive M, Harten I, Mitchell R, Beers J, Djabali K, Cao K, Erdos M, Blair C, Funke B, Smoot L, et al: Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010;30:2301-2309.
20.
Scaffidi P, Misteli T: Lamin A dependent misregulation of adult stem cells associated with accelerated aging. Nat Cell Biol 2008;10:452-459.
21.
Kandert S, Lüke Y, Kleinhenz T, Neumann S, Lu W, Jeagar V, Munck M, Wehnert M, Muller C, Zhou Z, et al: Nesprin-2 giant safeguards nuclear envelope architecture in LMNA S143F progeria cells. Hum Mol Genet 2007;16:2944-2959.
22.
Scaffidi P, Misteli T: Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 2005;11:440-445.
23.
Elmore L, Rehder C, Di X, McChesney P, Jackson-Cook C, Gewirtz D, Holt S: Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002;277:35509-35515.
24.
Liang L, Zhang H, Gu X: Homozygous LMNA mutation R527C in atypical Hutchinson-Gilford progeria syndrome: evidence for autosomal recessive inheritance. Acta Paediatr 2009;98:1365-1368.
25.
Garg A, Subramanyam L, Agarwal A, Simha V, Levine B, D'Apice M, Novelli G, Crow Y: Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J Clin Endocrinol Metab 2009;94:4971-4983.
26.
Ardestani P, Liang F: Sub-cellular localization, expression and functions of Sirt6 during the cell cycle in HeLa cells. Nucleus 2012;3:442-451.
27.
Ouellette M, McDaniel L, Wright W, Shay J, Schultz R: The establishment of telomerase-immortalized cell lines representing human chromosome instability syndromes. Hum Mol Genet 2000;9:403-411.
28.
Tivey H, Brook A, Rokicki M, Kipling D, Davis T: p38 (MAPK) stress signaling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes. Biogerontology 2013;14:47-62.
29.
Goldman R, Shumaker D, Erdos M, Eriksson M, Goldman A, Gordon L, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins F: Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2004;101:8963-8968.
30.
Liu Y, Rusinol A, Sinensky M, Wang Y, Zou A: DNA damage responses in progeroid syndromes arising from defective maturation of prelamin A. J Cell Sci 2006;2119:4644-4649.
31.
Musich P, Zou Y: Genomic instability and DNA damage responses in progeria arising from defective maturation of prelamin A. Aging 2009;1:28-37.
32.
Panier S, Boulton SJ: Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol 2014;15:7-18.
33.
Mao Z, Tian X, van Meter M, Ke Z, Gorbunova V, Seluanov A: Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence. Proc Natl Acad Sci USA 2012;109;11800-11805.
34.
McClintock D, Ratner D, Lokuge M, Owens D, Gordon L, Collins F, Djabali K: The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS One 2007;2:e1269.
35.
Kanfi Y, Shalman R, Peshtia V, Pilosofa S, Gozlana, Y, Pearsonb K, Lerrera B, Moazedc D, Marined J-C, Cabob R, et al: Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett 2008;582:543-548.
36.
Liu B, Wang J, Chan KM, Tija WM, et al: Genomic instability in laminopathy-based premature aging. Nat Med 2005;11:780-785.
37.
McCord R, Michishita E, Hong T, Berber E, Boxer L, Kusumoto R, Guan S, Shi X, Gozani O, Burlingame A, Bohr V, Chua K: SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging 2009;1:109-121.
38.
Lombard D, Schwer B, Alt F, Mostoslavsky R: SIRT6 in DNA repair, metabolism, and ageing. J Intern Med 2008;263:128-141.
39.
Tennen R, Bua D, Wright W, Chua K: SIRT6 is required for the maintenance of telomere position effect in human cells. Nat Commun 2011;2:433.
40.
DiMauro T, David G: Chromatin modification: the driving force of senescence and aging? Aging 2009;1:182-190.
41.
Hayden MS, Ghosh S: Shared principles in NF-κB signaling. Cell 2008;132:344-362.
42.
Kawahara T, Rapicavoli N, Wu A, Qu K, Quake S, Chang H: Dynamic chromatin localization of Sirt6 shapes stress- and aging-related transcriptional networks. PLoS Genet 2011;7:e1002153.
43.
Adler A, Sinha S, Kawahara T, Zhang J, Segal E, Chang H: Motif module map reveals enforcement of aging by continual NF-κB activity. Genes Dev 2007;21:3244-3257.
44.
Tilstra J, Robinson A, Wang J, Gregg S, Clauson C, Reay D, Nasto L, St Croix C, Usas A, Vo N, et al: NF-κB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest 2012;122:2601-2612.
45.
Dahl K, Scaffidi P, Islam M, Yodh A, Wilson K, Misteli T: Distinct structural and mechanical properties of the nuclear lamina in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2006;103:10271-10276.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
